Iceland· IS-EU/1/17/1225/001-002
Symtuza
A emtricitabine, tenofovir alafenamide, darunavir and cobicistat product containing emtricitabinum inn,darunavirum inn ethanólat,cobicistatum inn,tenofovirum alafenamidum inn fúmarat, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Emtricitabine, tenofovir alafenamide, darunavir and cobicistat is registered in 12 of 19 countries.
Countries holding a registration under ATC J05AR22 (emtricitabine, tenofovir alafenamide, darunavir and cobicistat), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Emtricitabine, tenofovir alafenamide, darunavir and cobicistat · ATC J05AR22
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Emtricitabinum INN,Darunavirum INN ethanólat,Cobicistatum INN,Tenofovirum alafenamidum INN fúmarat
- Manufacturer
- Janssen-Cilag International NV*
- Country
- Iceland (IS)
- ATC code
- J05AR22
- ATC class
- Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean40013430 stk x1 glasISK 138426
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AR22
Emtricitabine, tenofovir alafenamide, darunavir and cobicistat, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/48f7f948-b62f-49af-a17b-4b5f22f1294f GET /v1/drugs/48f7f948-b62f-49af-a17b-4b5f22f1294f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "J05AR22",
"marketed": true,
"strength": "800 mg/150 mg/200 mg/10 mg",
"ma_number": "EU/1/17/1225/001-002",
"substance": "Emtricitabinum INN,Darunavirum INN ethanólat,Cobicistatum INN,Tenofovirum alafenamidum INN fúmarat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42999"
}See everything about emtricitabine, tenofovir alafenamide, darunavir and cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.